Probiotic treatment induced change of inflammation related metabolites in IBS-D patients/double-blind, randomized, placebo-controlled trial

• Published in: Food science and biotechnology Vol. 29; no. 6; pp. 837 - 844
• Main Authors: Kim, Jinjoo, Cho, Kumsun, Kim, Joo Sung, Jung, Hyun Chae, Kim, Bumsik, Park, Myeong Soo, Ji, Geun Eog, Cho, Joo-Youn, Hong, Kyoung Sup
• Format: Journal Article
• Language: English
• Published: Singapore Springer Singapore 01.06.2020; Springer Nature B.V; 한국식품과학회
• Subjects: Bifidobacterium; Biomarkers; biotechnology; Chemistry; Chemistry and Materials Science; Diarrhea; Double-blind studies; Food Science; inflammation; Intestine; Irritable bowel syndrome; Lactobacillus; mechanism of action; Metabolites; metabolomics; methyl palmitate; Nutrition; Palmitic acid; placebos; prediction; Probiotics; urine; 식품과학; Probiotics; Metabolomics; Irritable bowel syndrome
• ISSN: 1226-7708; 2092-6456; 2092-6456
• DOI: 10.1007/s10068-019-00717-2

There have been many studies suggesting that probiotics are effective in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). However, its mechanism of action as well as prediction of response is still to be elucidated. In the present study, to find out metabolomic characteristics of probiotic effect in IBS-D, we compared IBS symptom changes and metabolomic characteristics in the subjects’ urine samples between multi-strain probiotics (one strain of Lactobacillus sp. and four strains of Bifidobacterium sp.) group (n = 32) and placebo group (n = 31). After 8 weeks’ administration (3 times/day), dissatisfaction in bowel habits and stool frequencies were significantly improved. Also, probiotics group had significantly changed seven metabolites including palmitic acid methyl ester (PAME) and 4,6-dihydroxyquinoline, 4-(2-aminophenyl)-2,4-dioxobutanoic acid (DOBA). According to IBS-SSS and IBS-QoL questionnaires, IBS-SSS responders showed higher PAME levels and IBS-QoL responders showed lower DOBA levels. This suggests potential role of these metabolites as a biomarker to predict probiotics effect in IBS-D patients.